6α,9-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-benzoyl-oxyandrosta-1,4-diene-17β-carbothioic acid | 398455-37-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6α,9-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-benzoyl-oxyandrosta-1,4-diene-17β-carbothioic acid
• 英文别名: (6S,8S,9R,10S,11S,13S,14S,16R,17R)-17-benzoyloxy-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioic S-acid
• CAS: 398455-37-3
• 化学式: C₂₈H₃₀F₂O₅S
• 分子量: 516.606
• InChiKey: BRKLTTWXZYBVCH-STSYBKACSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  81.7
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  硫代苯甲酸 、 6,9-二氟-11,17-二羟基-16-甲基-3-氧代雄甾-1,4-二烯-17-羧酸 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 6α,9-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-benzoyl-oxyandrosta-1,4-diene-17β-carbothioic acid
  参考文献：
  名称：

  PROCESS FOR SYNTHESIS OF ANDROSTANE 17-BETA CARBOTHIOIC ACID AND RELATIVE COMPOUNDS THEREOF

  摘要：

  提供一种合成雄甾烷17-β羧硫酸的方法。该方法包括混合雄甾烷17-β羧酸和偶联试剂，并添加烷硫酸以形成雄甾烷17-β羧硫酸，其中雄甾烷17-β羧硫酸的化学式为（I）：其中R1代表氢或卤代烷基，R2代表C1-8线性烷基，C1-8支链烷基，C1-6不饱和的无环基团或芳香基团，R3代表氢或羟基，R4代表氢、溴、氯或氟，R5代表氢、溴、氯或氟。该方法是一种单锅反应。

  公开号：

  US20090275767A1

文献信息

• Novel Anti-Inflammatory Androstane Derivatives
  申请人：Biggadike Keith

  公开号：US20080317833A1

  公开（公告）日：2008-12-25

  There are provided according to the invention pharmaceutical compositions comprising a compound of formula (I) wherein R 1 represents C 1-6 alkyl or C 1-6 haloalkyl; R 2 represents —C(═O)-aryl or —C(═O)-heteroaryl, wherein said heteroaryl is a 5 member heterocyclic aromatic ring containing 1-3 hetero atoms selected from N and S, or a 5 member heterocyclic aromatic ring containing 2-3 hetero atoms selected from N, O and S, or a 6 member heterocyclic aromatic ring containing 1-3 hetero atoms selected from N, O and S; R 3 represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; R 4 and R 5 are the same or different and each represents hydrogen or halogen; and represents a single or a double bond; or a physiologically acceptably salt or solvate thereof; and another therapeutically active agent; in admixture with one or more physiologically acceptable diluents or carriers.

  本发明提供了制剂，其中包括化合物(I)，其式中R1代表C1-6烷基或C1-6卤代烷基；R2代表—C(═O)-芳基或—C(═O)-杂芳基，其中所述的杂芳基是一个含有1-3个异原子（选自N和S）的5元杂环芳基环，或者是一个含有2-3个异原子（选自N、O和S）的5元杂环芳基环，或者是一个含有1-3个异原子（选自N、O和S）的6元杂环芳基环；R3代表氢、甲基（可以是α或β构型）或亚甲基；R4和R5相同或不同，且每个代表氢或卤素；并且代表单键或双键；或其生理上可接受的盐或溶剂；以及另一种治疗活性剂；与一种或多种生理上可接受的稀释剂或载体混合。
• NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES
  申请人：——

  公开号：US20030045512A1

  公开（公告）日：2003-03-06

  According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), 1 wherein R 1 represents C 1-6 alkyl or C 1-6 haloalkyl; R 2 represents —C(═O)-aryl or —C(═O)-heteroaryl; R 3 represents hydrogen, methyl (which may be in either the &agr; or &bgr; configuration) or methylene; R 4 and R 5 are the same or different and each represents hydrogen or halogen; and represents a single or a double bond; and salts and solvates thereof together with a long-acting &bgr; 2 -adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.

  根据本发明的一个方面，提供了一种用于吸入给药的药物配方，其包括式（I）的化合物，其中R1表示C1-6烷基或C1-6卤代烷基；R2表示—C（═O）-芳基或—C（═O）-杂环芳基；R3表示氢、甲基（可以处于α或β构型中）或亚甲基；R4和R5相同或不同，每个表示氢或卤素；表示单键或双键；以及其盐和溶剂合物，连同一种长效的β2-肾上腺素受体激动剂，该配方在治疗呼吸道炎症性疾病方面具有治疗上有用的效果，持续24小时或更长时间。
• Novel anti-inflammatory androstane derivatives
  申请人：Biggadike Keith

  公开号：US20050054622A1

  公开（公告）日：2005-03-10

  There are provided compounds of formula (I) wherein R 1 represents O, S or NH; R 2 represents —C(═O)-aryl or —C(═O)-heteroaryl; R 3 represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; R 4 and R 5 are the same or different and each represents hydrogen or halogen; and represents a single or a double bond; and salts and solvates thereof; process for preparing them, compositions containing them and their use in therapy.

  提供了化合物的公式（I），其中R1代表O，S或NH; R2代表—C（═O）-芳基或—C（═O）-杂环基; R3代表氢，甲基（可以是α或β构型）或亚甲基; R4和R5相同或不同，每个代表氢或卤素; 代表单键或双键; 以及其盐和溶剂化物; 制备它们的过程，含有它们的组合物以及它们在治疗中的用途。
• Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
  申请人：GLAXO GROUP LIMITED

  公开号：EP1757281A2

  公开（公告）日：2007-02-28

  According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents -C(=O)-aryl or -C(=O)-heteroaryl; R3 represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; R4 and R5 are the same or different and each represents hydrogen or halogen; and represents a single or a double bond; and salts and solvates thereof together with a long-acting β2-adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.

  根据本发明的一个方面，提供了一种用于吸入给药的药物制剂，其中包含式 (I) 化合物、 其中 R1 代表 C1-6 烷基或 C1-6 卤代烷基； R2 代表-C(＝O)-芳基或-C(＝O)-杂芳基； R3 代表氢、甲基（可以是 α 或 β 构型）或亚甲基； R4 和 R5 相同或不同，各自代表氢或卤素；以及 代表单键或双键； 及其盐类和溶剂，以及长效 β2-肾上腺素受体激动剂，该制剂在治疗呼吸道炎症性疾病方面具有 24 小时或更长时间的治疗作用。
• 17.BETA.-CARBOTHIOATE 17.ALPHA.-ARYLCARBONYLOXYLOXY ANDROSTANE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1305330B1

  公开（公告）日：2008-12-03